The Symplicity HTN-1 study demonstrated that renal denervation by radiofrequency ablation significantly reduced blood pressure (BP) in patients with drug-resistant hypertension at 1 and 12 months. A new analysis in the Lancet shows that this benefit was sustained at 3 years after therapy. Among 88 patients for whom data were complete at 36 months, systolic BP was reduced by 32.0 mmHg (95% CI −35.7 mmHg to −28.2 mmHg), and diastolic BP by 14.4 mmHg (95% CI −16.9 mmHg to −11.9 mmHg). The investigators conclude that “renal denervation seems to offer a novel and complementary approach for patients in whom pharmacological options seem exhausted. Adequately powered clinical trials with long-term follow-up are warranted to confirm these results”.